Literature DB >> 7460477

Physiologic mechanisms opposing the hemodynamic effects of prazosin.

J L Izzo, D Horwitz, H R Keiser.   

Abstract

Prazosin was give for 10 to 14 days to eight hypertensive patients on a fixed intake of dietary salt. Except as limited by side effects, the dose was increased from 2 mg/day to a maximum dose of 24 mg/day. During treatment, when subjects were studied in supine and upright positions, mean arterial pressure (MAP) fell 6% and 12% (p less than 0.025 and p less than 0.005), heart rate rose 3% and 9% (p less than 0.05 and p less than 0.005), and plasma norepinephrine increased 95% and 107% (p less than 0.01 and p less than 0.001) over control. Daily excretion of the norepinephrine metabolites methoxyhydroxyphenyl glycol (MHPG) and vanillylmandelic acid (VMA) increased 42% and 17% (p less than 0.05 for each) during treatment. There were no changes in average body weight or plasma renin for the group, but patients whose body weight increased tended to show less reduction in blood pressure (correlation coefficient, r = 0.72, p less than 0.05) and smaller increases in heart rate (r = -.073, p less than 0.05) during treatment with prazosin. These data suggest that expansion of extracellular fluid and activation of the sympathetic nervous system oppose the hemodynamic effects of prazosin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7460477     DOI: 10.1038/clpt.1981.2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.

Authors:  J Vincent; W Dachman; T F Blaschke; B B Hoffman
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine.

Authors:  M A Pfeifer; K Ward; T Malpass; J Stratton; J Halter; M Evans; H Beiter; L A Harker; D Porte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

3.  Chronic prazosin attenuates the natriuretic response to a modest saline load in anaesthetized rats.

Authors:  S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

Review 4.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.